WO1996001626A1 - Transdermal drug delivery system - Google Patents
Transdermal drug delivery system Download PDFInfo
- Publication number
- WO1996001626A1 WO1996001626A1 PCT/FI1995/000358 FI9500358W WO9601626A1 WO 1996001626 A1 WO1996001626 A1 WO 1996001626A1 FI 9500358 W FI9500358 W FI 9500358W WO 9601626 A1 WO9601626 A1 WO 9601626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- drug
- cyclodextrin
- polymer
- reservoir
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50413396A JP3734267B2 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
DK95922554T DK0764020T3 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
CA002193129A CA2193129C (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
AU27405/95A AU2740595A (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
DE69508938T DE69508938T2 (en) | 1994-07-08 | 1995-06-20 | TRANSDERMAL DRUG DELIVERY SYSTEM |
EP95922554A EP0764020B1 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
US08/765,766 US5817332A (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
FI970053A FI970053A0 (en) | 1994-07-08 | 1997-01-07 | Transdermal drug delivery system |
GR990401461T GR3030369T3 (en) | 1994-07-08 | 1999-05-28 | Transdermal drug delivery system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9413866.6 | 1994-07-08 | ||
GB9413866A GB2290964A (en) | 1994-07-08 | 1994-07-08 | Transdermal drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996001626A1 true WO1996001626A1 (en) | 1996-01-25 |
Family
ID=10758074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI1995/000358 WO1996001626A1 (en) | 1994-07-08 | 1995-06-20 | Transdermal drug delivery system |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817332A (en) |
EP (1) | EP0764020B1 (en) |
JP (1) | JP3734267B2 (en) |
AT (1) | ATE178485T1 (en) |
AU (1) | AU2740595A (en) |
CA (1) | CA2193129C (en) |
DE (1) | DE69508938T2 (en) |
DK (1) | DK0764020T3 (en) |
ES (1) | ES2130622T3 (en) |
GB (1) | GB2290964A (en) |
GR (1) | GR3030369T3 (en) |
WO (1) | WO1996001626A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19810951A1 (en) * | 1998-03-13 | 1999-09-16 | Deutsches Textilforschzentrum | Textile material useful for transdermal delivery of a drug which is incorporated into cyclodextrin fixed to the material |
EP1629844A1 (en) | 2004-07-13 | 2006-03-01 | Schering Oy | A longterm delivery system with controlled initial burst |
EP3054931A4 (en) * | 2013-10-07 | 2017-04-05 | Teikoku Pharma USA, Inc. | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980033113A (en) * | 1996-10-25 | 1998-07-25 | 야스다케 히지 | Aqueous solutions of local anesthetics, how to improve the solubility of local anesthetics, local anesthetics with reduced neurotoxicity and methods of reducing the neurotoxicity of local anesthetics |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
DE19814087A1 (en) | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Moisture-activated therapeutic system |
DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
CA2393762A1 (en) * | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6689378B1 (en) | 1999-12-28 | 2004-02-10 | Kimberly-Clark Worldwide, Inc. | Cyclodextrins covalently bound to polysaccharides |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
UA83341C2 (en) * | 2002-02-25 | 2008-07-10 | Дифьюжен Фармасьютикалз Ллк | Trans carotenoid bipolar salts and uses thereof |
WO2006104610A2 (en) * | 2005-02-24 | 2006-10-05 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US8287923B2 (en) * | 2005-06-10 | 2012-10-16 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating immune disorders |
US9446017B2 (en) | 2005-08-11 | 2016-09-20 | Augusta University Research Institute, Inc. | Compositions and methods for treating herpes simplex virus |
US20090252802A1 (en) * | 2006-04-07 | 2009-10-08 | Chang James N | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
EP2146948A4 (en) | 2007-04-13 | 2010-08-04 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
EA201070544A1 (en) * | 2007-10-31 | 2010-12-30 | Диффьюжн Фармасьютикалз Ллс | NEW CLASS OF THERAPEUTIC SUBSTANCES STRENGTHENING THE DIFFUSION OF LOW MOLECULAR COMPOUNDS |
KR101782023B1 (en) | 2009-06-22 | 2017-10-23 | 디퓨젼 파마슈티컬즈 엘엘씨 | Diffusion enhancing compounds and their use alone or with thrombolytics |
US20130017188A1 (en) | 2009-07-31 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
CN102884072A (en) | 2010-04-08 | 2013-01-16 | 爱默蕾大学 | Substituted androst-4-ene diones |
KR101891357B1 (en) | 2010-06-02 | 2018-08-24 | 디퓨젼 파마슈티컬즈 엘엘씨 | Oral formulations of bipolar trans carotenoids |
WO2012129237A2 (en) | 2011-03-20 | 2012-09-27 | Trustees Of Boston University | Therapeutic agent for emphysema and copd |
EP2704726B1 (en) | 2011-05-04 | 2018-10-31 | Trustees of Boston University | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2543370A1 (en) | 2011-07-06 | 2013-01-09 | Georgia Health Sciences University Research Institute, Inc. | Compositions and Methods for Treating Herpes Simplex Virus |
US9243037B2 (en) | 2011-11-10 | 2016-01-26 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
WO2015027146A1 (en) | 2013-08-22 | 2015-02-26 | The General Hospital Corporation | Inhibitors of human 12/15-lipoxygenase |
WO2015031765A2 (en) | 2013-08-29 | 2015-03-05 | Trustees Of Boston University | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections |
BR112016014404A2 (en) * | 2013-12-18 | 2017-08-08 | Gnt Llc | COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA |
EP3087985B1 (en) | 2013-12-18 | 2018-10-17 | Maruishi Pharmaceutical Co., Ltd. | Hydrous adhesive patch |
EP3303286B1 (en) | 2015-06-01 | 2023-10-04 | Cedars-Sinai Medical Center | Compounds that bind to rela of nf-kb for use in treating cancer |
BR112018001441A2 (en) | 2015-07-28 | 2018-09-11 | Vyome Biosciences Pvt Ltd | therapeutic and prophylactic antibacterials |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
JP7032320B2 (en) | 2016-03-24 | 2022-03-08 | ディフュージョン・ファーマシューティカルズ・エルエルシー | Use of bipolar transcarotenoids with chemotherapy and radiation therapy to treat cancer |
CA3045043A1 (en) | 2016-12-31 | 2018-07-05 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
JP2021529756A (en) | 2018-06-27 | 2021-11-04 | バイオエクセル セラピューティクス,インコーポレイテッド | Film preparation containing dexmedetomidine and its preparation method |
TWI772807B (en) | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | External preparation |
AU2020316013A1 (en) | 2019-07-19 | 2022-02-17 | Arx, Llc | Non-sedating dexmedetomidine treatment regimens |
CN117545474A (en) | 2021-11-08 | 2024-02-09 | 李维庸 | Transdermal drug delivery system for delivering a drug to a patient |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0197504A2 (en) * | 1985-04-05 | 1986-10-15 | Merck & Co. Inc. | pH-mediated drug delivery system |
WO1991009592A1 (en) * | 1989-12-21 | 1991-07-11 | Kabi Pharmacia Ab | Transdermal system |
EP0463653A1 (en) * | 1990-06-07 | 1992-01-02 | PHARMACIA S.p.A. | Galenic formulations containing cyclodextrins |
WO1992021338A1 (en) * | 1991-05-31 | 1992-12-10 | Orion-Yhtymä Oy | Medetomidine preparations for transdermal administration |
WO1993007858A1 (en) * | 1991-10-16 | 1993-04-29 | Arto Olavi Urtti | Peroral drug delivery system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4749574A (en) * | 1986-04-14 | 1988-06-07 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
HU210921B (en) * | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
-
1994
- 1994-07-08 GB GB9413866A patent/GB2290964A/en not_active Withdrawn
-
1995
- 1995-06-20 WO PCT/FI1995/000358 patent/WO1996001626A1/en active IP Right Grant
- 1995-06-20 JP JP50413396A patent/JP3734267B2/en not_active Expired - Lifetime
- 1995-06-20 EP EP95922554A patent/EP0764020B1/en not_active Expired - Lifetime
- 1995-06-20 AU AU27405/95A patent/AU2740595A/en not_active Abandoned
- 1995-06-20 CA CA002193129A patent/CA2193129C/en not_active Expired - Lifetime
- 1995-06-20 DK DK95922554T patent/DK0764020T3/en active
- 1995-06-20 ES ES95922554T patent/ES2130622T3/en not_active Expired - Lifetime
- 1995-06-20 AT AT95922554T patent/ATE178485T1/en active
- 1995-06-20 US US08/765,766 patent/US5817332A/en not_active Expired - Lifetime
- 1995-06-20 DE DE69508938T patent/DE69508938T2/en not_active Expired - Lifetime
-
1999
- 1999-05-28 GR GR990401461T patent/GR3030369T3/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0197504A2 (en) * | 1985-04-05 | 1986-10-15 | Merck & Co. Inc. | pH-mediated drug delivery system |
WO1991009592A1 (en) * | 1989-12-21 | 1991-07-11 | Kabi Pharmacia Ab | Transdermal system |
EP0463653A1 (en) * | 1990-06-07 | 1992-01-02 | PHARMACIA S.p.A. | Galenic formulations containing cyclodextrins |
WO1992021338A1 (en) * | 1991-05-31 | 1992-12-10 | Orion-Yhtymä Oy | Medetomidine preparations for transdermal administration |
WO1993007858A1 (en) * | 1991-10-16 | 1993-04-29 | Arto Olavi Urtti | Peroral drug delivery system |
Non-Patent Citations (1)
Title |
---|
EBERT C.D. ET AL: "Development of a novel transdermal system design", J. CONTROLLED RELEASE, vol. 6, AMSTERDAM, pages 107 - 111 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19810951A1 (en) * | 1998-03-13 | 1999-09-16 | Deutsches Textilforschzentrum | Textile material useful for transdermal delivery of a drug which is incorporated into cyclodextrin fixed to the material |
DE19810951B4 (en) * | 1998-03-13 | 2005-09-29 | Ciba Speciality Chemicals Holding Inc. | Use of a textile material as a transdermal delivery system and process for its preparation |
EP1629844A1 (en) | 2004-07-13 | 2006-03-01 | Schering Oy | A longterm delivery system with controlled initial burst |
EP3054931A4 (en) * | 2013-10-07 | 2017-04-05 | Teikoku Pharma USA, Inc. | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
Also Published As
Publication number | Publication date |
---|---|
JPH10502388A (en) | 1998-03-03 |
CA2193129C (en) | 2007-11-06 |
DE69508938T2 (en) | 1999-09-16 |
AU2740595A (en) | 1996-02-09 |
ES2130622T3 (en) | 1999-07-01 |
GB9413866D0 (en) | 1994-08-24 |
ATE178485T1 (en) | 1999-04-15 |
GR3030369T3 (en) | 1999-09-30 |
CA2193129A1 (en) | 1996-01-25 |
GB2290964A (en) | 1996-01-17 |
JP3734267B2 (en) | 2006-01-11 |
EP0764020B1 (en) | 1999-04-07 |
EP0764020A1 (en) | 1997-03-26 |
DK0764020T3 (en) | 1999-10-18 |
DE69508938D1 (en) | 1999-05-12 |
US5817332A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817332A (en) | Transdermal drug delivery system | |
US10596126B2 (en) | Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux | |
Kim et al. | Polymeric drug delivery systems | |
EP0519926B1 (en) | Transdermal system | |
Chien | Development of transdermal drug delivery systems | |
JP2002523446A (en) | Transdermal tolterodine as an antimuscarinic agent for the treatment of overactive bladder | |
JPH0220606B2 (en) | ||
Sugibayashi et al. | Polymers for transdermal drug delivery systems | |
CA2277367A1 (en) | Transdermal therapeutic system | |
Mertin et al. | In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: penetration of chloramphenicol from lipophilic vehicles and a nail lacquer | |
JPS61238721A (en) | Activator release-controlled unit dosage form | |
Jain et al. | Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride | |
Kondo et al. | Enhancement of transdermal delivery by superfluous thermodynamic potential. I. Thermodynamic analysis of nifedipine transport across the lipoidal barrier | |
AU2001281980B2 (en) | Dermal application system for amino laevulinic acid | |
Vasil'ev et al. | Transdermal therapeutic systems for controlled drug release (a review) | |
EP0238554A1 (en) | Liposome transdermal drug delivery system | |
EP0608306B1 (en) | Peroral drug delivery system | |
Banker et al. | Sustained-and Controlled-Release Drug-Delivery Systems | |
JP2775053B2 (en) | External preparation containing morphine | |
OGISO et al. | Percutaneous absorption of 1, 3-dinitroglycerin and a trial of pharmacokinetic analysis | |
Hymes | Transdermal drug delivery from a solid state hydrophilic reservoir system | |
Hema Navyatha | Design, Devolopment and Charecterization of Verapamil Hydrochloride Membrane Moderate Type Transdermal Patches | |
JPS63218630A (en) | Accelerator of percutaneous absorption | |
IE73249B1 (en) | Transdermal system | |
PT97192B (en) | TRANSDERMAL CONTROLLED LIBERATION SYSTEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LT LV MX NO NZ PL PT RO RU SG SI SK TJ UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2193129 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 970053 Country of ref document: FI Ref document number: 08765766 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995922554 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995922554 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995922554 Country of ref document: EP |